Free tool
FAERS Monitor: Bonsity
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211939 or its brand name (Bonsity, Teriparatide). Reports on generic versions are filed under their own applications.
Reports
7,181
Serious
4,999
70% of reports
Hospitalization
2,528
Death reported
411
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness527
- nausea525
- fall505
- fatigue487
- back pain474
- arthralgia462
- device malfunction452
- product dose omission issue436
- pain in extremity425
- pain398
- headache391
- device operational issue361
- malaise299
- asthenia280
- dyspnoea239
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 33 |
| 2006 | 16 |
| 2007 | 57 |
| 2008 | 40 |
| 2009 | 52 |
| 2010 | 44 |
| 2011 | 85 |
| 2012 | 307 |
| 2013 | 509 |
| 2014 | 150 |
| 2015 | 142 |
| 2016 | 129 |
| 2017 | 310 |
| 2018 | 437 |
| 2019 | 492 |
| 2020 | 228 |
| 2021 | 185 |
| 2022 | 299 |
| 2023 | 476 |
| 2024 | 986 |
| 2025 | 1,382 |
| 2026 | 812 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,978 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device operational issueSignal | 361 | 268.2 | 241.4 | 87,817 |
| device malfunctionSignal | 452 | 19.0 | 17.3 | 7,646 |
| back painSignal | 474 | 6.0 | 5.5 | 1,981 |
| fallSignal | 505 | 4.4 | 4.1 | 1,367 |
| product dose omission issueSignal | 436 | 4.3 | 4.0 | 1,135 |
| pain in extremitySignal | 425 | 4.2 | 3.9 | 1,058 |
| arthralgiaSignal | 462 | 3.3 | 3.0 | 734 |
| dizzinessSignal | 527 | 3.1 | 2.9 | 763 |
| astheniaSignal | 280 | 2.2 | 1.9 | 181 |
| malaise | 299 | 2.0 | 1.8 | 151 |
| nausea | 525 | 1.9 | 1.8 | 249 |
| pain | 398 | 1.9 | 1.7 | 173 |
| fatigue | 487 | 1.8 | 1.7 | 190 |
| headache | 391 | 1.8 | 1.7 | 150 |
| dyspnoea | 239 | 1.2 | 1.1 | 11 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.